
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is increasingly attractive because its revenue reset appears to reflect known customer and managed-service headwinds rather than weakening demand, while the underlying platform is producing stronger profitability and cash flow. In 3Q, revenue was $21.6M, EBITDA reached $6.3M with a 29.1% margin, gross margin expanded to 75.2%, and free cash flow was $4.7M, showing meaningful operating leverage as the cost base resets lower. The balance sheet has also improved to net cash, contracted revenue for 2027 is running about 20% ahead of last year, and new programmatic DSP integrations plus the return of a top-5 client create credible upside.
Bears say
OptimizeRx is facing a fundamentally fragile revenue base, with net revenue retention dropping to 90% from 121% and three customers each accounting for more than 10% of 2025 revenue, while roughly 62% of 2025 revenue flowed through just two channel partners. This concentration leaves the business exposed to partner leverage, customer budget shifts, and execution missteps, especially after management acknowledged that commercial execution issues contributed to the loss of a major customer relationship. At the same time, the May 2025 executive order, the December 2025 CMS MFN proposal, and IRA drug-pricing pressure threaten the pharma marketing budgets that support demand, while the unwind of lower-margin managed services could create near-term revenue volatility if automation does not scale fast enough.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About OptimizeRx Corp (OPRX) Forecast
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares